Branded Generics Market by Product (Trade Named Generics, Value-Added), Drug Type (Alkylating Agents, Anti-depressants, Anti-epileptics), Route of Administration, Indication, Distribution Channel - Global Forecast 2024-2030

Branded Generics Market by Product (Trade Named Generics, Value-Added), Drug Type (Alkylating Agents, Anti-depressants, Anti-epileptics), Route of Administration, Indication, Distribution Channel - Global Forecast 2024-2030

The Branded Generics Market size was estimated at USD 432.30 billion in 2023 and expected to reach USD 494.29 billion in 2024, at a CAGR 14.66% to reach USD 1,126.43 billion by 2030.

Branded generic drugs refer to medications that are bioequivalent to the original innovator drug and are distributed under a different brand name by another company after patent expiration. These drugs are formulated using the same active pharmaceutical ingredients (APIs) as the innovator product and must meet similar regulatory requirements for manufacturing processes, safety profiles, and efficacy standards. However, branded generics may exhibit subtle differences in terms of excipients, packaging materials, or manufacturing techniques compared to their innovator counterparts. Increasing consumer awareness about accessible treatment options, rising healthcare expenditure, and increasing patent expirations on blockbuster drugs drive the growth of the branded generics market. However, stringent regulatory requirements for drug approval and quality control and price erosion resulting from intense competition among manufacturers may hinder market growth. Nevertheless, advancements in pharmaceutical research enabling the development of bioequivalent products create lucrative opportunities for the growth of the branded generics market.

Regional Insights

In the Americas region, the branded generics market has a lucrative landscape due to its robust healthcare infrastructure and high per capita spending on pharmaceuticals. The government's initiatives to increase awareness about generic drugs have led to promising growth prospects for branded generics. Additionally, the investment in R&D by leading pharmaceutical companies has resulted in new product approvals and innovative therapeutics entering this market space. The European Union showcases a diverse landscape within the branded generics sector. There is considerable demand for cost-effective treatment options with increasing healthcare expenditure across EU countries and favorable pricing policies for generic medicines by national governments. Major players are investing heavily in research activities to develop novel drugs while maintaining competitiveness against low-cost alternatives from emerging markets. The Middle East and Africa offer notable potential for growth in the branded generics market as the government initiatives aimed at improving healthcare infrastructure and affordability of medicines are driving factors contributing to expanding market opportunities. The Asia-Pacific showcases immense potential for branded generics development owing to the rising research and development, supportive government initiatives, increasing demand for trade generics, and surging collaborations among international players to develop innovative therapies catering to global needs.

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the Branded Generics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • Prevalence of chronic diseases necessitating the use of generic medications
    • Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
    • Market Restraints
      • Concerns associated with quality variations in branded generic medications
      • Market Opportunities
        • Novel bioequivalence studies and efforts by market players to expand branded generics business
        • Market Challenges
          • Litigation issues and issues related to price erosion of innovator drugs
          • Market Segmentation Analysis
            • Product: Significant adoption of value-added branded generics due to their additional advantages
            • Drug Type: High usage of anti-hypertensive for treating high blood pressure
            • Route of Administration: Wide adoption of oral route due to their longer duration of action
            • Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases
            • Distribution Channel: Evolving online distribution channels for branded generics
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Branded Generics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Branded Generics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • Vyvanse Generics Approved by FDA
              
              The FDA has approved generic forms of Vyvanse - (Lisdexamfetamine Dimesylate) for the treatment option of ADHD in patients aged six years or older, as well as moderate-to-severe BED in adults. Takeda Pharmaceuticals' U.S. patent for Vyvanse expired, allowing companies to manufacture and sell generic versions of the medication. These generic versions may contain different binding agents, fillers, and colors.
              
              Pharmaceutical Alliance, Generic Pharmaceutical Association Renew Generic Drug Pricing Agreement
              
              The pan-Canadian Pharmaceutical Alliance (pCPA) & the Canadian Generic Pharmaceutical Association (CGPA) have renewed a three-year pricing initiative for generic medicines. This initiative aims to effectively manage public drug plan costs while providing a stable and predictable environment for generics manufacturers to introduce new drugs. As a part of the new initiative, any new generics entering the pan-Canadian Tiered Pricing Framework automatically reduce their prices to 55% of the brand reference price after three months, provided that there is only one generic product available in Canada.
              
              Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
              
              Amneal Pharmaceuticals, Inc. introduced its authorized generic version of Xyrem1 (Sodium Oxybate) oral solution CIII in the United States. This medication is commonly prescribed to address cataplexy or excessive daytime sleepiness (EDS) by acting as a central nervous system depressant. In addition to this launch, Amneal has obtained Abbreviated New Drug Application (ANDA) approvals from the U.S. FDA for five complex generic products.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Branded Generics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the Branded Generics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ajanta Pharma Ltd., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Apotex Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Aurobindo Pharma Limited, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Endo International PLC, Eris Lifesciences Limited, Eva Pharma, Fresenius Kabi AG, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Lupin Limited, Micro Labs Limited, Nichi-Iko Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH by Novartis AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., and Zentiva Group, a.s..
            
            Market Segmentation & Coverage
            
            This research report categorizes the Branded Generics Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Product
              • Trade Named Generics
              • Value-Added
              • Drug Type
                • Alkylating Agents
                • Anti-depressants
                • Anti-epileptics
                • Anti-hypertensive
                • Anti-psychotics
                • Antimetabolites
                • Hormones
                • Lipid Lowering Drugs
                • Route of Administration
                  • Oral
                  • Parenteral
                  • Topical
                  • Indication
                    • Acute & Chronic Pain
                    • Cardiovascular Diseases
                    • Dermatological Diseases
                    • Gastrointestinal Diseases
                    • Neurological Diseases
                    • Oncology
                    • Distribution Channel
                      • Offline
                        • Hospital Pharmacy
                        • Retail Pharmacy
                        • Online
                        • Region
                          • Americas
                            • Argentina
                            • Brazil
                            • Canada
                            • Mexico
                            • United States
                              • California
                              • Florida
                              • Illinois
                              • New York
                              • Ohio
                              • Pennsylvania
                              • Texas
                              • Asia-Pacific
                                • Australia
                                • China
                                • India
                                • Indonesia
                                • Japan
                                • Malaysia
                                • Philippines
                                • Singapore
                                • South Korea
                                • Taiwan
                                • Thailand
                                • Vietnam
                                • Europe, Middle East & Africa
                                  • Denmark
                                  • Egypt
                                  • Finland
                                  • France
                                  • Germany
                                  • Israel
                                  • Italy
                                  • Netherlands
                                  • Nigeria
                                  • Norway
                                  • Poland
                                  • Qatar
                                  • Russia
                                  • Saudi Arabia
                                  • South Africa
                                  • Spain
                                  • Sweden
                                  • Switzerland
                                  • Turkey
                                  • United Arab Emirates
                                  • United Kingdom
                                  
                                  
                                  Please Note: PDF & Excel + Online Access - 1 Year